1
|
Shanthini K, Manivannan V, Govindan R, Praburaman L, Al-Humaid LA, Oh TH, Vignesh S. Facile construction of efficient WO 3/V 2O 5 coupled g-C 3N 4 ternary composite photocatalyst for environmental emergent aqueous pollutant degradation: Stability, degradation reaction pathway and effect of pH evaluation. ENVIRONMENTAL GEOCHEMISTRY AND HEALTH 2024; 46:376. [PMID: 39167294 DOI: 10.1007/s10653-024-02152-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2024] [Accepted: 07/29/2024] [Indexed: 08/23/2024]
Abstract
Currently, one of the primary challenges that human society must overcome is the task of decreasing the amount of energy used and the adverse effects that it has on the environment. The daily increase in liquid waste (comprising organic pollutants) is a direct result of the creation and expansion of new companies, causing significant environmental disruption. Water contamination is attributed to several industries such as textile, chemical, poultry, dairy, and pharmaceutical. In this study, we present the successful degradation of methylene blue dye using g-C3N4 (GCN) mixed with WO3 and V2O5 composites (GCN/WO3/V2O5 ternary composite) as a photocatalyst, prepared by a simple mechanochemistry method. The GCN/WO3/V2O5 ternary composite revealed a notable enhancement in photocatalytic performance, achieving around 97% degradation of aqueous methylene blue (MB). This performance surpasses that of the individual photocatalysts, namely pure GCN, GCN/WO3, and GCN/V2O5 composites. Furthermore, the GCN/WO3/V2O5 ternary composite exhibited exceptional stability even after undergoing five consecutive cycles. The exceptional photocatalytic activity of the GCN/WO3/V2O5 ternary composite can be ascribed to the synergistic effect of metal-free GCN and metal oxides, resulting in the alteration of the band gap and suppression of charge recombination in the ternary photocatalyst. This study offers a better platform for understanding the characteristics of materials and their photocatalytic performance under visible light conditions.
Collapse
|
2
|
Patel B, Pepin K, Li S, Davies S, Rohatgi A, Herzog B, Ward J, Baggstrom M, Waqar S, Morgensztern D, Govindan R, Devarakonda S. PP01.28 Tumor Engraftment is Prognostic for Disease Recurrence in Resected Non-Small Cell Lung Cancer. J Thorac Oncol 2023. [DOI: 10.1016/j.jtho.2022.09.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
3
|
Veerapandi G, Govindan R, Sekar C. Quick and accurate determination of hazardous phenolic compounds using CaCu 2O 3 nanorods based electrochemical sensor. CHEMOSPHERE 2023; 313:137370. [PMID: 36435324 DOI: 10.1016/j.chemosphere.2022.137370] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Revised: 11/15/2022] [Accepted: 11/22/2022] [Indexed: 06/16/2023]
Abstract
In the present work, we report the fabrication of a novel electrochemical sensor based on nanostructured CaCu2O3 as electrode material for the simultaneous determination of 2-Aminophenol (o-AP), 2-Chlorophenol (o-CP) and 2-Nitrophenol (o-NP). Nanorods-shaped CaCu2O3 have been synthesized by chemical precipitation method and characterized by powder X-ray diffraction (XRD), X-ray photo-electron microscopy (XPS), field emission electron microscopy (FESEM) and high-resolution transmission electron microscopy (HRTEM). Glassy carbon electrodes (3 mm diameter) have been modified using CaCu2O3 nanorods by drop-casting method. Cyclic voltammetry (CV) studies at CaCu2O3/GCE exhibited excellent electrochemical behaviours towards the oxidation of 2-AP, 2-CP and 2-NP at different potentials well separated from each other. The CaCu2O3/GCE displayed the lowest detection limits of 5.74 nM (0.626 ppb), 1.38 nM (0.177 ppb) and 1.03 nM (0.143 ppb) for 2-AP, 2-CP and 2-NP respectively over wide measurable linear ranges of 175 nM-68 μM (2-AP), 50 nM-90 μM (2-CP) and 25 nM-32 μM (2-NP). Cyclic stability studies showed a loss of 7%, 13% and 14% from initial current responses after conducting 100 cycles of CV for 2-AP, 2-CP and 2-NP in PBS (pH 7.0) which indicated the excellent stability of the fabricated electrode. Reproducibility studies of six different CaCu2O3/GCEs exhibited good recoveries in the order of 3.23% (2-AP), 3.54% (2-CP) and 2.46% (2-NP) respectively. The fabricated electrode with excellent sensitivity, stability and reproducibility has been successfully applied for the determination of 2-AP, 2-CP and 2-NP simultaneously in tap water and agricultural water samples. Selectivity studies carried out on CaCu2O3/GCE revealed its ability to detect 4-aminophenol and 4-nitorphenol at different oxidation potentials. High performance liquid chromatography (HPLC) studies have been carried out to validate the practical utility of the fabricated sensor.
Collapse
|
4
|
Champiat S, Boyer M, Paz-Ares L, Schoenfeld A, Izumi H, Govindan R, Carlisle J, Borghaei H, Johnson M, Steeghs N, Vokes E, Dowlati A, Zhang Y, Pati A, Ju CH, Mukherjee S, Chen X, Hashemi Sadraei N, Hummel HD. 147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer. IMMUNO-ONCOLOGY AND TECHNOLOGY 2022. [DOI: 10.1016/j.iotech.2022.100259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
5
|
Borghaei H, Paz-Ares L, Johnson M, Champiat S, Owonikoko T, Lai V, Boyer M, Hummel HD, Govindan R, Steeghs N, Blackhall F, Reguart N, Dowlati A, Zhang Y, Sadraei NH, Goldrick A, Izumi H. OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
6
|
Herzog B, Waqar S, Devarakonda S, Ward J, Govindan R, Morgensztern D. EP08.01-013 Ramucirumab plus Atezolizumab in Patients with Stage IV NSCLC Previously Treated with Immune Checkpoint Blockade. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Li B, Falchook G, Durm G, Burns T, Skoulidis F, Ramalingam S, Spira A, Bestvina C, Goldberg S, Veluswamy R, Iams W, Chiappori A, Lemech C, Meloni A, Ebiana V, Dai T, Gauto D, Varrieur T, Snyder W, Govindan R. OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.025] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Nagasaka M, Goto K, Gomez J, Hida T, Shu C, Lee C, Park K, Cho B, Lee J, Ou S, Bestvina C, Natale R, Haddish-Berhane N, Bhattacharya A, Verheijen R, Agrawal T, Knoblauch R, Govindan R. P50.04 Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Skoulidis F, Schuler M, Wolf J, Barlesi F, Price T, Dy G, Govindan R, Borghaei H, Falchook G, Li B, Ramalingam S, Sacher A, Spira A, Takahashi T, Anderson A, Ang A, Dai T, Flesher D, Cifuentes P, Velcheti V. MA14.03 Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Park K, Sabari J, Haura E, Shu C, Spira A, Salgia R, Reckamp K, Sanborn R, Govindan R, Bauml J, Curtin J, Xie J, Roshak A, Lorenzini P, Millington D, Thayu M, Knoblauch R, Cho B. 1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1852] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
11
|
Paz-Ares L, Owonikoko T, Johnson M, Govindan R, Izumi H, Lai V, Borghaei H, Boyer M, Boosman R, Hummel HD, Blackhall F, Dowlati A, Zhang Y, Mukherjee S, Sable B, Pati A, Shetty A, Sadraei NH, Champiat S. 48MO Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC). J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01890-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Pellini B, Hasan S, Samson P, Earland N, Ward J, Waqar S, Baggstrom M, Robinson C, Govindan R, Devarakonda S, Morgensztern D. P49.03 Chemoradiation with Cisplatin-Etoposide versus Carboplatin-Etoposide in Limited-Stage Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Antao N, Samson P, Pellini B, Waqar S, Devarakonda S, Ward J, Govindan R, Morgensztern D. P09.26 Cause of Death in Patients with Squamous Cell Lung Cancer (SCC) Treated with Surgery. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Li B, Skoulidis F, Falchook G, Sacher A, Velcheti V, Dy G, Price T, Borghaei H, Schuler M, Kato T, Takahashi T, Spira A, Ramalingam S, Besse B, Barlesi F, Tran Q, Henary H, Ngarmchamnanrith G, Govindan R, Wolf J. PS01.07 Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.321] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Knapp B, Mezquita L, Devarakonda S, Aldea M, Waqar S, Pepin K, Ward J, Botticella A, Howarth K, Knape C, Morris C, Govindan R, Besse B, Morgensztern D. FP07.11 Circulating Tumor DNA (ctDNA) Clearance as a Biomarker in Patients With Locally Advanced NSCLC Following Chemoradiation. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Altan M, Govindan R, Schoenfeld A, Noujaim J, Sacher A, Haanen J, Huang C, Hasan A, Faitg T, Butler E, Shalabi A, Owonikoko T. P14.19 CD8α-Enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
17
|
Spigel D, Rodríguez-Abreu D, Cappuzzo F, Velcheti V, Ganti A, Johnson D, Govindan R, Antonia S, Besse B, Altan M, Edelman M, Ramalingam S, Felip E, Gadgeel S, Juan-Vidal O, Gupta A, Currie S, Lin W, Tagliaferri M, Reck M. P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
18
|
Fakih M, Durm G, Govindan R, Falchook G, Soman N, Henary H, Hong D. MO01.30 Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.135] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
19
|
Hong D, Bang YJ, Barlesi F, Durm G, Falchook G, Govindan R, Dy G, Park K, Strickler J, Burns T, Kim J, Ang A, Lipford J, Ngarmchamnanrith G, Anderson A, Li B. MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.136] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Hong D, Bang YJ, Barlesi F, Durm G, Falchook G, Govindan R, Dy G, Park K, Strickler J, Burns T, Kim J, Ang A, Lipford J, Ngarmchamnanrith G, Anderson A, Li B. 1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1571] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
21
|
Gillette M, Satpathy S, Cao S, Dhanasekaran S, Vasaikar S, Krug K, Petralia F, Li Y, Liang WW, Reva B, Hong R, Savage S, Getz G, Li Q, Zhang B, Rodriguez H, Ruggles K, Robles A, Clauser K, Govindan R, Wang P, Nesvizhskii A, Ding L, Mani D, Carr S. A02 Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. J Thorac Oncol 2020. [DOI: 10.1016/j.jtho.2019.12.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Govindan R, Fakih M, Price T, Falchook G, Desai J, Kuo J, Strickler J, Krauss J, Li B, Denlinger C, Durm G, Ngang J, Henary H, Ngarmchamnanrith G, Rasmussen E, Morrow P, Hong D. P2.15-C Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.181] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Govindan R, Fakih M, Price T, Falchook G, Desai J, Kuo J, Strickler J, Krauss J, Li B, Denlinger C, Durm G, Ngang J, Henary H, Ngarmchamnanrith G, Rasmussen E, Morrow P, Hong D. OA01.06 Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Garon E, Govindan R, Papadimitrakopoulou V, Wang C, Varea R, Kim J, Aerts J. P1.01-73 An Explorative Analysis of Pemetrexed +/- Pembrolizumab Maintenance from KEYNOTE-189 Versus PARAMOUNT, PRONOUNCE, and JVBL. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Govindan R, Fakih M, Price T, Falchook G, Desai J, Kuo J, Strickler J, Krauss J, Li B, Denlinger C, Durm G, Ngang J, Henary H, Ngarmchamnanrith G, Rasmussen E, Morrow P, Hong D. Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.008] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|